CHALFONT ST GILES, England--(BUSINESS WIRE)--July 31, 2006--GE Healthcare, a unit of General Electric Company (NYSE:GE - News) today announced that GE Healthcare has exercised the exclusive option to license PhotoCure’s product Hexvix® (hexaminolevulinate), an optical molecular imaging agent intended for the diagnosis and monitoring of bladder cancer, for the US market. This is an extension of the agreement signed earlier this year that afforded GE Healthcare exclusive global rights outside of the Nordic region to market and distribute PhotoCure’s product Hexvix. PhotoCure continues to be responsible for manufacturing and Nordic distribution of the product. This license, which is subject to government approval related to competition laws in the US, grants GE the right to market and sell Hexvix in the United States pending U.S. Food and Drug Administration (FDA) approval of the drug for use.
